About Veyond Metaverse Team| Veyond Metaverse

Adam Choe, MBA
Co-Founder & CEO

Adam Choe co-founded Veyond Metaverse in 2021. As the CEO, he defined the Veyond Metaverse vision and strategy, contributed to core values, and has led the company since its inception. Prior to Veyond Metaverse, Adam was CEO of two successful healthcare companies, Immunostics and NanoEnTek USA, where he commercialized products globally and defined the company's growth areas. Adam was the first employee at Johnson and Johnson Lifescan Korea, where he served as a founding Managing Director. There he developed the core brand and drove strategy and execution of commercial functions. Adam successfully served as a vice president of global health management at Alere (Now Abbott). Adam received an MBA in marketing and strategy from Carnegie Mellon University and a BA in Biology from the University of Texas at Austin.

Joon Chung, PhD
Co-Founder & CTO

Joon Chung co-founded Veyond Metaverse in 2021 and has served as Chief Technology Officer of Veyond Metaverse since its founding. As the CTO, he defined the Veyond Metaverse technology roadmap and vision. He is a driving force behind our technical know-how and capabilities. Joon established a global network of collaborators and research institutes that will enable the technology leadership for Veyond Metaverse for years to come. Prior to Veyond Metaverse, he is a full professor at Ryerson University and a director of the MIMS (Mixed-reality Immersive Motion Simulation) lab. He has published extensively in his field. Joon earned his Master and PhD in Aerospace Engineering from Cornell University and University of Toronto.

Pr. Thierry Flam, MD
Co-Founder & Chief Medical Officer

Thierry is a urologist. He is currently attending urological surgeon, Fondation Saint Jean de Dieu, and urologist, Brachytherapy unit at the Institute Curie, Paris. His area of interest ranges from clinical and basic research in the field of urologic oncology, mainly in the treatment of prostate cancer, research on bladder cancer, and the development of surgical simulators. He is a pioneer of the introduction of laser treatment of the prostate and prostate brachytherapy in France. From 1995 until 2014, he served as Professor of Urology at the Hospital Cochin, a leading academic medical center in Paris. He trained as a Resident in urology both in Paris and at the Lahey Clinic in Boston, where he also served as Assistant Resident in Surgery at Harvard Medical School. He received his medical education and MD degree in Paris.

William Chapman, PhD
CSO

William has 25 years of experience working for numerous clinical, life sciences, and analytical service companies as a leader, liaison, and key contributor, gaining extensive knowledge in chemistry, medicine, and life sciences. He has a proven record of developing strategies that yield positive, measurable results, especially in areas of new technology development, and is highly skilled in interacting and collaborating with members of other technical professions to meet mission-critical objectives. He believes that the validation of new devices needs to be considered carefully in the early design phase and that the resulting quality is absolutely necessary for market acceptance. He earned his Ph.D. in Chemistry from Penn State University and continued his studies as an NIH Postdoctoral fellow at Columbia University.

James Snider

James has extensive experience in product development and operations in both startup and large companies. Prior to joining Critical Diagnostics, James was the Executive Vice President of Business & Operations for IntelligentMD, an early-stage medical device company that focuses on the essential elements of disease diagnostics and therapeutic intervention. Previously, he spent eight years at Applied Biosystems (ABI). James holds a B.S. in chemistry from Grand Valley State University and a Ph.D. in chemistry from the University of South Carolina.

Jim McMenamy

Jim McMenamy has spent the last 30+ years focusing primarily on the development and worldwide launch of numerous Human and Veterinary Clinical Diagnostic Test Systems with a specific focus on the Point of Care Marketplace. He has launched dozens of new products in areas such as Infectious Diseases, Cancer Markers, Fertility Tests, Drugs of Abuse etc. both Instrumented and non-Instrumented. He has held leadership positions in Marketing, Sales, Business Development, Corporate Development and General Management with companies such as Samsung (NexusDx), Becton Dickinson, Quidel, ACON Labs, Alere/Inverness Medical, scil/Henry Schein Animal Health and diatron/Stratec Corp. Jim holds a BS Degree in Biomedical Engineering and an MBA from Rutgers University.

John Erickson

John Erickson is a dynamic and strategic senior global health care business leader with success-based experience from Fortune 50 to start-ups including: Johnson & Johnson, Abbott, Bio-Rad, Nexus Dx and as a consultant to diabetes, clinical diagnostic and life science companies. John has been recognized for proven leadership in delivering superior results, developing profitable growth strategies and building high performance teams. Additionally, John has been responsible for the development, launch and management of over 3 dozen scientific products with cumulative revenues in excess of $4 billion and has raised more than $50 million in investment capital. John’s experiential portfolio and business acumen also includes strategy development and execution, capital funding, organizational design and cultural change management, numerous global new product launches, joint venture management, corporate partnerships, product licensing agreements, intellectual property strategy, Digital Health and Point of Care (POC), and emerging market development expertise.

About us

Veyond Metaverse

TEAM

ADVISORS